BIOGEN INC. Debt Securities, Available-for-sale, Noncurrent
BIOGEN INC. (BIIB) had Debt Securities, Available-for-sale, Noncurrent of $465.60 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-04-29
- 2026-03-31: Debt Securities, Available-for-sale, Noncurrent $465.60M.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $431.90M.
- 2024-12-31: Debt Securities, Available-for-sale, Noncurrent $0.00.
- 2023-12-31: Debt Securities, Available-for-sale, Noncurrent $0.00.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2026-03-31 | $465.60M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $431.90M 10-Q · filed 2026-04-29 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-06 |
| 2023-12-31 | $0.00 10-K · filed 2024-02-14 |
| 2023-09-30 | $100.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.21B 10-Q · filed 2023-07-25 |
| 2023-03-31 | $978.20M 10-Q · filed 2023-04-25 |
| 2022-12-31 | $705.70M 10-K · filed 2024-02-14 |
| 2022-09-30 | $860.30M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $1.10B 10-Q · filed 2022-07-20 |
| 2022-03-31 | $1.00B 10-Q · filed 2022-05-03 |
| 2021-12-31 | $892.00M 10-K · filed 2023-02-15 |
| 2021-09-30 | $968.30M 10-Q · filed 2021-10-20 |
| 2021-06-30 | $915.10M 10-Q · filed 2021-07-22 |
| 2021-03-31 | $821.90M 10-Q · filed 2021-04-22 |
| 2020-12-31 | $772.10M 10-K · filed 2022-02-03 |
| 2020-09-30 | $1.01B 10-Q · filed 2020-10-21 |
| 2020-06-30 | $922.80M 10-Q · filed 2020-07-22 |
| 2020-03-31 | $969.50M 10-Q · filed 2020-04-23 |
| 2019-12-31 | $1.41B 10-K · filed 2021-02-03 |
| 2019-09-30 | $1.81B 10-Q · filed 2019-10-22 |
| 2019-06-30 | $1.31B 10-Q · filed 2019-07-24 |
| 2019-03-31 | $1.37B 10-Q · filed 2019-04-24 |
| 2018-12-31 | $1.38B 10-Q · filed 2019-10-22 |
| 2018-09-30 | $1.24B 10-Q · filed 2018-10-23 |
| 2018-06-30 | $1.16B 10-Q · filed 2018-07-24 |
| 2017-12-31 | $3.06B 10-Q · filed 2018-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |